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ABS TRACT
Lay Summary: We probed the evolutionary robustness of two antivirulence drugs, gallium and flucyto-
sine, targeting the iron-scavenging pyoverdine in the opportunistic pathogen Pseudomonas aeruginosa.
Using an experimental evolution approach in human serum, we showed that antivirulence treatments
are not evolutionarily robust per se, but vary in their propensity to select for resistance.
Background and objectives: Treatments that inhibit the expression or functioning of bacterial virulence
factors hold great promise to be both effective and exert weaker selection for resistance than conven-
tional antibiotics. However, the evolutionary robustness argument, based on the idea that antivirulence
treatments disarm rather than kill pathogens, is controversial. Here, we probe the evolutionary robust-
ness of two repurposed drugs, gallium and flucytosine, targeting the iron-scavenging pyoverdine of the
opportunistic human pathogen Pseudomonas aeruginosa.
Methodology: We subjected replicated cultures of bacteria to two concentrations of each drug for 20 consecutive
days in human serum as an ex vivo infection model. We screened evolved populations and clones for resistance
phenotypes, including the restoration of growth and pyoverdine production, and the evolution of iron uptake by-
passing mechanisms. We whole-genome sequenced evolved clones to identify the genetic basis of resistance.
Results:We found that mutants resistant against antivirulence treatments readily arose, but their selective spreading
varied between treatments. Flucytosine resistance quickly spread in all populations due to disruptive mutations in
upp, a gene encoding an enzyme required for flucytosine activation. Conversely, resistance against gallium arose
only sporadically, and was based on mutations in transcriptional regulators, upregulating pyocyanin production, a
redox-active molecule promoting siderophore-independent iron acquisition. The spread of gallium resistance was
presumably hampered because pyocyanin-mediated iron delivery benefits resistant and susceptible cells alike.
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Conclusions and implications: Our work highlights that antivirulence treatments are not evolutionarily
robust per se. Instead, evolutionary robustness is a relative measure, with specific treatments occupying
different positions on a continuous scale.
KEYWORDS : antivirulence therapy; experimental evolution; Pseudomonas aeruginosa; gallium;
flucytosine; drug resistance
INTRODUCTION
There is currently much interest in therapeutic approaches that
inhibit the expression or functioning of bacterial virulence factors
[1–8]. Virulence factors are structures and molecules that allow
bacteria to establish and maintain infections [9, 10]. Examples of
virulence factors include flagella and pili to adhere to the host tis-
sue, secreted enzymes, tissue-damaging toxins and siderophores
to scavenge iron from the host [11]. Approaches that target these
traits are called antivirulence treatments. There is great hope that
disarming rather than killing pathogens is an efficient and evolu-
tionarily robust way to manage infections [2, 12–15]. In particular, it
is assumed that antivirulence treatments exert weaker selection for
resistance than conventional antibiotics because pathogens
are not killed directly. However, empirical evidence for the evolu-
tionary robustness of antivirulence treatments is controversial
with positive and negative reports currently balancing each other
out [16–21].
The controversy entails both conceptual and practical aspects.
On the conceptual level, some define antivirulence approaches as
treatments that specifically target virulence factors without affecting
pathogen growth [2, 22], while others argue that it is unlikely that
virulence factors do not affect pathogen fitness, and thus simply use
the mechanistic part of the definition [5, 15]. On the practical level,
there are debates about what exactly a resistance phenotype is [15],
as it could include restoration of virulence factor production, growth
(if affected), and/or the activation of a bypassing mechanism,
restoring the virulence phenotype [19]. Moreover, there is a short-
age of studies examining resistance evolution under realistic con-
ditions in replicated populations, both at the phenotypic and
genetic level.
Here, we tackle these issues by examining the mechanistic and
evolutionary potential of resistance evolution against two
repurposed drugs, gallium and flucytosine, which both target
the iron-scavenging pyoverdine of the opportunistic human
pathogen Pseudomonas aeruginosa [19, 23, 24]. Pyoverdine is an
important virulence factor during acute infections [19, 25–31]. It is
required to obtain iron from host proteins, such as transferrin and
lactoferrin [32]. Given its importance, it has been proposed that
drugs interfering with iron uptake could be effective therapeutics
to control infections [33]. Gallium and flucytosine both fulfill this
role, albeit through different modes of action. Gallium, a
repurposed cancer drug, is an iron-mimic and binds irreversibly
to secreted pyoverdine, thereby rendering the molecules useless
for iron uptake [19, 23, 31]. Flucytosine, a repurposed antifungal
drug, enters the bacterium, where it is enzymatically activated to a
fluorinated ribonucleotide. This active form inhibits, via a yet un-
known mechanism, the expression of the pvdS iron starvation
sigma factor controlling pyoverdine synthesis [24, 34].
In a first set of experiments, we examined whether these two drugs
affect the growth of P. aeruginosa in human blood serum, a medium
that has recently been established as an ex vivo infection model [35].
We hypothesize that gallium and flucytosine are likely to reduce
pathogen fitness as they induce iron starvation [19, 23, 36, 37].
In addition, antivirulence drugs, like any other drugs, might have
deleterious off-target effects affecting growth. Gallium at high dos-
age, for instance, can penetrate into bacterial cells, where it interferes
with redox-active enzymes [38, 39]. Flucytosine, once activated,
is known to affect RNA synthesis, which might negatively affect
growth [40].
In a second experiment, we examined whether mutants, resistant
against these two repurposed drugs, evolve and spread through
bacterial populations. To this end, we exposed replicated popula-
tions of P. aeruginosa to two different concentrations of gallium and
flucytosine in human serum. Together with a drug-free control treat-
ment, we let the treated populations evolve for 20 consecutive days
in 8-fold replication, by transferring a fraction of the evolving cul-
tures to fresh human serum on a daily basis. Following experimental
evolution, we screened evolved populations and clones for possible
resistance phenotypes, including the restoration of growth, restor-
ation of virulence factor production and the evolution of a bypassing
mechanism for iron uptake [15, 19]. Finally, we sequenced the whole
genome of evolved clones to uncover the genetic basis of potential
resistance mechanisms.
Resistance evolution requires two processes: the supply of mu-
tations conferring resistance and appropriate selection regimes
favoring the spread of these mutants [41]. With regard to mutation
supply, some common resistance mechanisms (e.g. drug degrad-
ation, prevention of drug influx and increased drug efflux) are less
likely to apply for gallium, which is an ion and acts outside the cell
[19]. Therefore, with fewer possible routes to resistance being avail-
able, we predict gallium to show higher evolutionarily robustness
than flucytosine. However, as for the spread of mutants, both drugs
could be evolutionarily robust because they target a secreted viru-
lence factor, which can be shared as a public good between patho-
gen individuals (iron-loaded pyoverdine can be taken up by all
bacteria with a matching receptor) [42, 43]. Consequently, if resist-
ance entails the resumption of virulence factor production then
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resistant mutants should not spread because they bear the cost of
resumed virulence factor production, whilst sharing the benefit with
everyone else in the population, including the drug-susceptible in-
dividuals [12, 14, 16, 20]. Conversely, if these drugs have deleterious
off-target effects, we predict the evolutionary robustness to decline,
and accelerated spread of resistance under drug exposure, as for
traditional antibiotics.
METHODOLOGY
Strains and culturing conditions
We used the genetically well-characterized P. aeruginosa PAO1
wildtype strain for all experiments. For some assays, we further
used a set of knockout mutants in the PAO1 background as
control strains (see Supplementary Table S1). Overnight cul-
tures were grown in 8 ml Lysogeny broth (LB) in 50-ml Falcon
tubes, incubated at 37C, 200 rpm for 18 h. For all experiments,
we washed overnight cultures with 0.8% NaCl solution and ad-
justed them to OD600 =2.5. Bacteria were further diluted to a final
starting of OD600 =2.5 103. All experiments were carried out
in human serum, supplemented with HEPES (50 mM) to buffer
the medium at physiological pH. Moreover, to impose a
standardized iron limitation across experiments, we added the
iron chelator human apo-transferrin (100 mg/ml), which is typic-
ally present in blood serum at high concentration, and its co-
factor NaHCO3 (20 mM). We used gallium (GaNO3) and flucyto-
sine (5-fluorocytosine) as antibacterials. All chemicals,
including human serum, were purchased from Sigma-Aldrich,
Switzerland.
Growth and virulence factor inhibition curves
To assess the extent to which gallium and flucytosine inhibit PAO1
growth and pyoverdine production, we subjected bacterial cul-
tures to a seven-step antibacterial concentration gradient: 0–
512mM for GaNO3 and 0–140mg/ml for flucytosine. Overnight
cultures of bacteria were grown and diluted as described above
and inoculated into 200ml of human serum on 96-well plates.
Plates were incubated at 37C in a Tecan Infinite M-200 plate
reader (Tecan Group Ltd., Switzerland). We tracked growth by
measuring OD at 600 nm and pyoverdine-associated natural
fluorescence (excitation: 400 nm, emission: 460 nm) every 15 min
for 24 h. Plates were shaken for 15 s (3 mm orbital displacement)
prior to each reading event.
Experimental evolution
We exposed wildtype cultures of PAO1 to experimental evolution
for 20 days under five different selective regimes in 8-fold replica-
tion. The five regimes included a no-drug control, and a low and a
high concentration treatment for both drugs (gallium: 50 and
280mM; flucytosine: 10 and 140mg/ml). The antibacterial concen-
trations were inferred from the dose–response curves (Fig. 1). To
initiate experimental evolution, an overnight culture of PAO1 was
grown as described above, and individual wells on a 96-well plate
were inoculated with 10ml of culture (diluted to a final density of
106 cells per well) in 190ml iron-limited human serum. Incubation
occurred in the plate reader at 37C for 23.5 h, and OD600 was
measured every 15 min prior to a brief shaking event.
Subsequently, cultures were diluted in 0.8% NaCl and transferred
to a new plate containing fresh media. We adjusted the dilution
factor proportional to the overall growth per treatment; no-drug
control: 2103 (days 1–10) and 4103 (days 11–20); antibac-
terial treatments: 103 (days 1–10) and 2103 (days 11–20).
Following transfers, we added 100ml of a 50% glycerol–LB solu-
tion to cultures for storage at 80C.
Quantification of resistance profiles
To test whether populations evolved under antibacterial exposure
restored growth and/or pyoverdine production, we exposed
evolved lineages to the drug concentrations they experienced dur-
ing experimental evolution in 5-fold replication. Following a stand-
ard protocol with incubation at 37C, shaking at 160 rpm, for 24 h
[44], we compared the OD600 and pyoverdine-associated fluores-
cence of evolved lineages relative to the ancestor wildtype grown
under drug and no-drug treatment.
To assess potential resistance profiles of individual clones, we
streaked out aliquots of evolved lineages onto LB plates. After
overnight incubation at 37C, we randomly picked 200 clones
(5 colonies per lineage), and assessed their growth and
pyoverdine production in 3-fold replication, as described above.
Moreover, we performed an in-depth analysis for 20 (four per
treatment) randomly picked single clones by quantifying their
drug–inhibition curve, following the protocol described above.
To test whether bacteria upregulated alternative iron-acquisi-
tion mechanisms, we quantified pyocyanin and protease produc-
tion of selected clones. For pyocyanin production, overnight
bacterial cultures were inoculated into 1 ml of LB (starting
OD600 =10
6), and incubated at 37C for 24 h, shaken at 160 rpm.
We measured pyocyanin in the cell-free supernatant through ab-
sorbance at 691 nm [19]. For protease production, overnight bac-
terial cultures were inoculated in human serum (starting OD600
=2.5103), and incubated at 37C for 24 h, shaken at 160 rpm.
Subsequently, we centrifuged cultures at 3700 rpm for 15 min to
obtain protease-containing supernatants. To measure proteolytic
activity, we adapted the protocol by [45]: 0.1 ml azocasein solution
(30 mg/ml) were mixed with 0.3 ml 50 mM phosphate buffer (pH
7.5), and 0.1 ml culture supernatant. During incubation at 37C
(2 h), proteases hydrolyze azocasein and release the azo-dye.
Proteolytic reaction was stopped by adding 0.5 ml 20% trichloro-
acetic acid, samples centrifuged at 12 000 rpm (10 min), and
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proteolytic activity measured through absorbance of the azo-dye
at 366 nm.
Sequencing analysis
We further isolated the genomic DNA of the selected 16 clones
evolved under drug regimes and sequenced their genomes. We
used the GenElute Bacterial Genomic DNA kit (Sigma Aldrich) for
DNA isolation. DNA concentrations were assayed using the
Quantifluor dsDNA sample kit (Promega). Samples were sent
to the Functional Genomics Center Zurich for library preparation
(Nextera XT) and sequencing. Sequencing was performed on the
Illumina HiSeq 4000 platform with single-end 125 base pair reads.
Adapter sequences were clipped using Trimmomatic v0.33 [46]
and reads trimmed using Flexbar v2.5 [47]. We aligned the reads to
the PAO1 reference genome using BWA v0.7.12 [48]. We applied
GATK v3.5 [49] indel realignment, duplicate removal and
HaplotypeCaller SNP/INDEL discovery according to the GATK
Best Practices recommendations. This generated a variant call
format (VCF) file, from which the following variants were
discarded: (i) coverage <20 reads; (ii) Fisher Strand score
>30.0, ensuring that there is no strand bias in the data; (iii) QD
value <2.0 (confidence value that there is a true variation at a
given site); and (iv) clustered variants (3 variants in 35 nt win-
dow) as they likely present sequencing or alignment artifacts. This
filtering process yielded a list of potential SNPs and small INDELs,
which we annotated using snpEff 4.1g [50] and then screened
manually, compared with the sequenced genome of our ancestor
wildtype for relevant mutations in gene coding and intergenic re-
gions (Supplementary Table S2).
Statistical analysis
We used RStudio for statistical analysis (version 0.99.896, with R
version 3.3.0). We analyzed growth curves and pyoverdine pro-
duction profiles using the grofit package [51]. We fitted nonpara-
metric model (Splines) curves to estimate growth yield and
integral (area under the curve). For all analyses, we scaled growth
yield and pyoverdine production relative to the untreated ances-
tral wildtype. We used general linear mixed effect models to
A B
C D
Figure 1. Gallium and flucytosine affect both growth and pyoverdine production ofP. aeruginosa in human serum (HS). Both antivirulence drugs reduce growth of
bacterial cultures in a dose–dependent manner (A, B), albeit following different patterns: gallium curbs bacterial growth only at relatively high concentrations (A),
whereas flucytosine already reduces growth at low concentrations (B). Both drugs further affect pyoverdine production (C,D). When increasing gallium exposure,
bacteria first upregulate pyoverdine production at intermediate drug concentrations, but then down-scale investment levels at high drug concentrations (C). In
contrast, flucytosine administration leads to an almost complete abolishment of pyoverdine production even at the lowest drug concentration. All data are
expressed as average of growth yield, scaled relative to the drug-free treatment. Error bars denote standard errors of the mean across 6 (for flucytosine) and 18 (for
gallium) replicates. Dose–response curves were fitted using a spline fit. Vertical lines indicate the drug concentrations used in the experimental evolution
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compare whether growth parameters or pyoverdine profiles differ
in evolved cultures treated with or without antibacterials. To test
for differences between evolved lines and the ancestral wildtype,
we used Welch’s two-sample t-test. To compare the dose–re-
sponse curve of evolved clones, we first fitted spline curves to
the inhibition curves, then estimated the integrals of these fits,
and compared the scaled fits relative to the ancestor wildtype
using analysis of variance (ANOVA). Protease and pyocyanin pro-
duction of evolved clones and the ancestor wildtype were cor-
rected for cell number (OD600) and analyzed using ANOVA.
RESULTS
Gallium and flucytosine curb growth and pyoverdine
production in human serum
To confirm that human serum is an iron-limited media, in which
pyoverdine is important for growth, we compared the growth of
our wildtype strain PAO1 with the pyoverdine-negative mutant
PAO1 pvdD in either pure human serum or human serum sup-
plemented with transferrin (Supplementary Fig. S1). As expected
for iron-limited media, we observed significantly reduced growth
of the siderophore-deficient mutants compared with the wildtype
(ANOVA: t49 =8.13, P< 0.0001) under both conditions.
We then subjected PAO1 to a range of drug concentrations in
human serum supplemented with transferrin. The resulting dose–
response curves revealed that both drugs significantly affected
growth and pyoverdine production, albeit following different pat-
terns (Fig. 1). For gallium, growth reduction was moderate at low
concentrations, and only became substantial at high concentra-
tions (GaNO3 256 mM, Fig. 1A). Gallium treatment affected
pyoverdine synthesis in a complex way (Fig. 1C), yet consistent
with previous findings [19]: at intermediate gallium concentra-
tions, pyoverdine is up-regulated to compensate for the gallium-
induced pyoverdine inhibition, and down-regulated at higher
concentrations, when pyoverdine-mediated signaling becomes
impaired [23]. For flucytosine, already the lowest concentration
caused a substantial growth reduction (Fig. 1B) and completely
stalled pyoverdine production, with the reduction remaining fairly
constant across the concentration gradient (Fig. 1D). We ob-
tained similar response profiles when growing PAO1 in human
serum without added transferrin (Supplementary Fig. S2),
indicating that transferrin supplementation does not affect the
drugs’ mode of actions. For all subsequent experiments, we used
human serum with added transferrin to ensure strong iron limi-
tation and to standardize conditions across experiments.
Do bacteria evolve population-level resistance to
antivirulence treatments?
We subjected PAO1 wildtype cultures to experimental evolution
both in the absence and presence of gallium and flucytosine (two
concentrations each). Eight independent lines per treatment were
daily transferred to fresh human serum for a period of 20 days.
Subsequently, we assessed whether evolved populations im-
proved growth and/or pyoverdine production levels compared
with the treated ancestral wildtype, which could provide first hints
of resistance evolution.
For growth (Fig. 2A), we found that evolved lines grew signifi-
cantly better under drug exposure than the ancestral wildtype
(Welch’s t-tests, gallium low (50 mM): t11.9 =4.96, P = 0.0003;
gallium high (280 mM): t13.3 =6.48, P< 0.0001; flucytosine low
(10mg/ml): t12.2 =5.09, P = 0.0002; flucytosine high (140 mg/ml):
t7.5 =11.79, P< 0.0001). Because growth increase could simply
reflect adaptation to media components other than drugs, we also
analyzed changes in growth performance of the lines evolved with-
out drugs. It turned out that some of the untreated evolved lin-
eages also showed improved growth compared with the ancestral
wildtype, but the overall increase across lines was not significant
(t9.1 =1.61, P = 0.1424, Fig. 2A).
For pyoverdine production, we observed no significant change
for the lines evolved under low gallium concentration (compari-
son relative to the treated ancestor, Welch’s t-test: t8.8 =0.94,
P = 0.3719) (Fig. 2B). Conversely, lines evolved under the other
three drug regimes all showed significantly increased pyoverdine
production (Fig. 2B) (gallium high: t13.1 =3.69, P = 0.0026; flu-
cytosine low: t7.2 =7.64, P = 0.0001; flucytosine high: t9.6
=54.65, P< 0.0001). While the increase was moderate for the
gallium high treatment, there was full restoration of pyoverdine
production in both flucytosine treatments (no significant differ-
ence relative to the ancestral untreated wildtype, ANOVA, flucyto-
sine low: t88 =1.31, P = 0.1944; flucytosine high: t88 =0.42,
P = 0.6766). Although pyoverdine restoration might be taken as
evidence for resistance evolution, analysis of the control lines
shows that a significant increase in pyoverdine production also
occurred in the absence of drugs (Welch’s t-test, t9.1 =4.03,
P = 0.0047, Fig. 2B).
Screening for resistance profiles in evolved single clones
While the population analyses above show that drug resistance
and general media adaptation could both contribute to the
evolved population growth and pyoverdine phenotypes, we
decided to screen individual clones for in-depth analysis. In a first
step, we isolated 200 random clones (i.e. 40 per treatment), and
individually analyzed their growth and pyoverdine production.
These analyses revealed high between-clone variation in growth
and pyoverdine production (Supplementary Figs S3 and S4), sug-
gesting that most evolved populations were heterogeneous, con-
sisting of multiple different genotypes. Interestingly, we observed
that 25% of the evolved clones from the no-drug control lines lost
the ability to produce pyoverdine (Supplementary Fig. S4). This
observation matches the results from previous studies, showing
that iron-limitation selects for nonproducers that cheat on the
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pyoverdine produced by others [52, 53]. Increased pyoverdine pro-
duction at the population level (Fig. 2B) is then typically the result
of wildtype cells over-compensating for the presence of nonpro-
ducers [54, 55]. Conversely, we did not detect nonproducers in the
four drug treatments, which suggest that selection pressures dif-
fer between the nondrug and the drug treatments.
In a second step, we randomly picked 16 single clones (4 per
drug treatment) and tested whether these evolved clones differ in
their drug dose response curve relative to the ancestral wildtype.
We observed that three out of eight clones subjected to gallium
(Fig. 3A–D) and all eight clones subjected to flucytosine showed a
significantly altered dose response (Fig. 3E–H). Clones GL_2 and
GL_3, evolved under low gallium, showed a significant increase in
pyoverdine production under intermediate gallium concentra-
tions (between 8 and 128mM), which goes along with an improved
growth performance for GL_2, but not GL_3. In contrast, clone
GH_1, evolved under high gallium concentration, did not show an
altered pyoverdine production response, but grew significantly
better when exposed to gallium (Fig. 3A–D). For the eight clones
evolved under the flucytosine regime, changes in the dose–re-
sponse curves were both striking and uniform: growth and
pyoverdine production were no longer affected by the drug
(Fig. 3E–H). Since these dose–response curves directly include
a control for media adaptation (i.e. the no-drug treatment), our
results indicate that all eight clones evolved complete resistance
to flucytosine. For gallium, on the other hand, our data suggest
that three out of the eight clones exhibited a phenotype that is
compatible with at least partial resistance. To check whether
these putative resistance profiles are unique to clones evolved
under drug treatment, we further assessed the dose–response
curves of four clones from the no-drug control lines
(Supplementary Fig. S5). All these clones responded to both
drugs in the same way as the susceptible ancestral wildtype, con-
firming that adaptation to human serum does not per se result in
resistant phenotypes.
Linking phenotypes to genotypes
Our whole-genome sequencing of the 16 focal clones revealed a
small number of SNPs and INDELs, which have emerged during
experimental evolution (Table 1). All the clones evolved under
flucytosine treatment had acquired mutations in the coding se-
quence of upp. There were 4 different types of mutations,
including two different nonsynonymous SNPs, a 15-bp deletion
A
B
Figure 2. Population level growth and pyoverdine production after evolution in human serum. PAO1 cultures were exposed to either no treatment, low (50 mM) or
high (280 mM) gallium, low (10mg/ml) or high (140 mg/ml) flucytosine concentrations during a 20-day experimental evolution experiment in 8-fold replication.
Following evolution, we assessed growth and pyoverdine production of evolved populations (displayed on the x-axis) and compared their performance relative
with the untreated (gray solid line, set to 1) and treated ancestral wildtype (black dashed line). (A) Compared with the treated ancestral wildtype, growth of evolved
populations significantly increased under all treatment regimes. Growth also increased in some but not all of the nontreatment lines. (B) Pyoverdine production of
evolved populations significantly increased relative to the untreated ancestral wildtype under all conditions, also in the no treatment lines. This indicates that
increased pyoverdine production might be a general response to growth in human serum, which makes it difficult to disentangle resistance evolution from media
adaptation. Error bars show the standard error of the mean across five independent replicates
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and a 1-bp insertion (Supplementary Table S3). The upp gene
encodes for a uracil phosphoribosyl-transferase, an enzyme
required for the intra-cellular activation of flucytosine [56, 57].
For the clones evolved under gallium treatment, the mutational
pattern was more heterogeneous (Table 1). No mutations were
detected for three clones (GH_2, GH_3, GH_4). In contrast, the
three clones with significantly altered dose responses had
mutations potentially explaining their phenotypes: clone GH_1
featured a 3-nt deletion in mvaU, whereas the clones GL_2 and
GL_3 were mutated in vfr. Both genes encode transcriptional regu-
lators involved in the regulation of virulence factors, including
proteases, pyocyanin and pyoverdine.
In addition, several clones had mutations in dipA (dispersion-
induced phosphodiesterase A; GL_1, GL_4, FH_4) and morA
A B
C D
E F
G H
Figure 3. Changes in dose–response curves for evolved single clones indicate resistance evolution. 16 randomly picked clones, four per treatment, were exposed
to a range of drug concentrations to test whether their dose–response altered during evolution compared with the ancestral wildtype (black circles and lines). (A,B)
Growth dose–response curves under gallium treatment show that two evolved clones (GL_2 and GH_1) are significantly less inhibited than the ancestral wildtype.
(C, D) Pyoverdine doseresponse curves under gallium treatment show that two evolved clones (GL_2 and GL_3) make significantly more pyoverdine than the
ancestral wildtype. (E, F) Growth doseresponse curves under flucytosine treatment show that all evolved clones grow significantly better than the ancestral
wildtype, and are in fact no longer affected by the drug. (G,H) Pyoverdine doseresponse curves under flucytosine treatment show that all evolved clones produce
significantly more pyoverdine than the ancestral wildtype, and are in fact no longer affected by the drug. Growth and pyoverdine production were measured after
24 h. For each clone, values are scaled relative to its performance in human serum without drugs (absolute values of pyoverdine and growth in the absence of
treatment are reported in Supplementary Fig. S6). We used spline functions to fit doseresponse curves, and used the integral (area under the curve) to quantify
the overall dose response of each clone across the concentration gradient. Error bars denote standard errors of the mean across six replicates. Asterisks represent
significance levels: *P< 0.05; ***P< 0.0001, based on linear model with df=45
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Table 1. List of mutations in evolved single clones
Treatment Clone Genea Description Mutation Type Positionb
Gallium Low GL_1 dipA Dispersion-induced phospho-
diesterase A
CA ! C INDEL 5642855–5642856
GL_2 vfr Transcriptional regulator C ! T SNP 706108
GL_3 vfr Transcriptional regulator C ! T SNP 706108
PA3801 Conserved hypothetical
protein
A ! G SNP 4260811
morA Motility regulator G ! T SNP 5158144
GL_4 dipA Dispersion-induced phospho-
diesterase A
CA ! C INDEL 5642855–5642856
Gallium High GH_1 mvaU Transcriptional regulator GAGC ! G INDEL 3016276–3016279
GH_2 None
GH_3 None
GH_4 None
Flucytosine Low FL_1 upp Uracil phosphoribosyl-
transferase
T ! C SNP 5213244
yfiR Tripartite signaling complex C ! T SNP 1214975
PA1369 Hypothetical protein C ! T SNP 1483680
PA2770-PA2771 Intergenic region G ! A SNP 3129202
FL_2 upp Uracil phosphoribosyl-
transferase
GAGAAGATCT
CCGGGA ! G
INDEL 5213011–5213037
FL_3 upp Uracil phosphoribosyl-
transferase
A ! C SNP 5212855
upp Uracil phosphoribosyl-
transferase
A ! G SNP 5213146
FL_4 upp Uracil phosphoribosyl-
transferase
T ! C SNP 5213244
groEL Protein chaperone G ! A SNP 4916838
PA2770-PA2771 Intergenic region G ! A SNP 3129202
Flucytosine High FH_1 upp Uracil phosphoribosyl-
transferase
G ! GC INDEL 5212852
upp Uracil phosphoribosyl-
transferase
A ! C SNP 5212855
fliF Flagella M-ring outer mem-
brane protein precursor
CA ! C INDEL 1194060–1194061
FH_2 upp Uracil phosphoribosyl-
transferase
A ! C SNP 5212855
morA Motility regulator G ! A SNP 5159713
FH_3 upp Uracil phosphoribosyl-
transferase
A ! C SNP 5212855
fliF Flagella M-ring outer mem-
brane protein precursor
TCGTCC ! T INDEL 1193365–1193370
FH_4 upp Uracil phosphoribosyl-
transferase
A ! C SNP 5212855
dipA Dispersion-induced phospho-
diesterase A
GA ! G INDEL 5643059–5643060
aOnly mutations not found in the ancestor wildtype PAO1 are reported. Common mutations among all samples and the ancestor are listed in
Supplementary Table S2.
bPosition on PAO1 reference genome.
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(motility regulator; GL_3, FH_2). The repeated yet unspecific ap-
pearance of these mutations could suggest that they represent
nondrug-specific adaptations to human serum. Altogether, our
sequencing analysis identified three potential targets explaining
resistance evolution: the gene upp for flucytosine, and the genes
encoding the transcriptional regulators vfr and mvaU for gallium.
Evolution of bypassing mechanisms for iron acquisition
under gallium treatment
It was proposed that bypassing mechanisms, which guarantee
iron uptake in a siderophore-independent manner, could confer
resistance to gallium [19]. One such by-passing mechanism could
involve the up-regulation of pyocyanin, a molecule that can reduce
ferric to ferrous iron outside the cell, thereby promoting direct iron
uptake [18, 58]. This scenario indeed seems to apply to the three
clones mutated in mvaU or vfr, two regulators that control directly
(mvaU) or indirectly (vfr) the expression of pyocyanin [59, 60].
These clones displayed significantly increased pyocyanin produc-
tion compared with the ancestral wildtype (Fig. 4A; ANOVA,
GH_1: t79 =9.64, P< 0.0001; GL_2: t99 =6.13, P< 0.0001; GL_3:
t99 =14.8, P< 0.0001).
A second by-passing mechanism could operate via increased
protease production, which would allow iron acquisition from
transferrin or heme through protease-induced hydrolysis [29,
61]. We found no support for this hypothesis. In fact, six of the
evolved clones exhibited reduced and not increased protease ac-
tivity (Fig. 4B). Moreover, the two clones with significantly
increased protease activity (ANOVA, GL_1: t10 =13.22,
P< 0.0001; GL_4: t10 =11.60, P< 0.0001, Fig. 4B) did not show
an altered drug dose–response curve.
Inactivation of Upp is responsible for resistance to
flucytosine
Next, we tested whether the mutations in upp are responsible for
flucytosine resistance. The enzyme Upp (uracil phosphoribosyl-
transferase) is essential for the activation of flucytosine within the
cell. The natural function of Upp is to convert uracil to the nucleo-
tide precursor UMP in the salvage pathway of pyrimidine (Fig. 5A).
However, P. aeruginosa can also produce UMP through the con-
version of L-glutamine and L-aspartate [62] (Fig. 5A), suggesting
that upp is not essential for pyrimidine metabolism. Mutations in
this gene could thus prevent flucytosine activation, and confer
drug resistance. To test this hypothesis, we compared the flucyto-
sine dose–response curve of the wildtype strain with an isogenic
(transposon) mutant (MPAO1upp). Consistent with the pat-
terns of the evolved clones (Fig. 3G), we found that
MPAO1upp was completely insensitive to flucytosine, with nei-
ther growth (Fig. 5B) nor pyoverdine production (Fig. 5C) being
affected by the drug. These results indicate that upp inactivation is
a simple and efficient mechanism to become flucytosine resistant.
A B
Figure 4. Upregulation of pyocyanin or protease production as potential bypassing mechanisms for iron acquisition under gallium treatment. The eight
sequenced clones evolved under gallium treatments (low: 50 mM, high: 280mM) were screened for their change in the secretion of pyocyanin (A) and proteases
(B) relative to the ancestral wildtype. Standard protocols were used for the phenotypic screens in drug free media (see Methodology for details). All values are
corrected for cell number, and scaled relative to the ancestor wildtype (black line). We included the strains PAO1rhlR (deficient for pyocyanin production) and
PAO1lasR (deficient for protease production) as negative controls in the respective assays (dashed lines). Error bars denote standard errors of the mean across
three (for proteases) and eight (for pyocyanin) replicates. Asterisks represent significance levels: *P< 0.05; ***P< 0.0001, based on ANOVA.
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DISCUSSION
New treatment approaches against the multi-drug resistant
ESKAPE pathogens, to which P. aeruginosa belongs, are desper-
ately needed [8, 63, 64]. In this context, treatments that disarm
rather than kill bacteria have attracted particular interest, because
such approaches have been proposed to be both effective in
managing infections and sustainable in the sense that resistance
should not easily evolve [2, 5, 12–15]. Promising approaches in-
clude the quenching of toxins [65, 66], siderophores required for
iron-scavenging [19, 23, 24, 37, 67], and quorum sensing mol-
ecules regulating virulence factor production [3]. In our study,
we probed the evolutionary robustness argument by focusing
on two repurposed drugs (gallium and flucytosine) targeting sid-
erophore production of P. aeruginosa. Using a combination of
replicated experimental evolution and phenotypic and genotypic
analysis, we show that the often-recited argument of antivirulence
drugs being evolutionarily robust is not supported. Instead, we
provide a nuanced view on the molecular mechanisms and se-
lective forces that can lead to resistance. For flucytosine, for in-
stance, we found repeated resistance evolution based on a
mechanism that prevents drug activation inside the cell, which
mitigates possible pleiotropic and deleterious effects caused by
this drug. For gallium, meanwhile, two types of partially resistant
mutants, based on siderophore bypassing mechanisms, arose.
However, these mutants only sporadically emerged, indicating
that their potential to selectively spread in populations is
compromised. Our work highlights that evolutionary robustness
is a relative measure with specific treatments lying on different
positions on a continuum. Thus, our task is not to argue about
whether antivirulence drugs are evolutionarily robust or not, but
to assess the relative position of each novel treatment on this
continuum.
A
B C
Figure 5. Upp is a nonessential enzyme, and mutations in its gene result in flucytosine resistance. (A) Flucytosine interferes with the pyrimidine metabolism in P.
aeruginosa. The drug enters the cell through the transporter CodB (not shown), where it is first converted to fluorouracil by the cytosine deaminase CodA, and then
to fluoro-UMP by the uracil phosphoribosyl-transferase Upp. Fluoro-UMP is a modified nucleotide precursor, the action of which results in RNA molecules with
compromised functionality. Through an as yet unknown mechanism, fluoro-UMP also arrests pyoverdine synthesis in P. aeruginosa. Importantly, the nucleotide-
precursor UMP can also be produced through an alternative de-novo pathway from the amino acids L-glutamine and L-aspartate, making Upp a nonessential
enzyme in this bacterium. Experiments with the transposon mutant MPAO1 Dupp (deficient for Upp production) indeed demonstrate that the lack of Upp no
longer affects strain growth (B) and pyoverdine production (C). This demonstrates that the inactivation of upp is a simple and efficient way to evolve resistance to
flucytosine. Experiments were carried out in human serum across a range of flucytosine concentrations. Growth and pyoverdine production of MPAO1Dupp (gray-
dashed lines) and its corresponding wildtype MPAO1 (black-solid lines) were measured after 24 h for each treatment separately in 6-fold replication. All values are
scaled relative to the drug-free treatment. For statistical analysis, we compared the integrals of the dose–response curves between the mutant and the wildtype
strain (Welch’s t-test, growth: t4.3=5.56, P = 0.0041; pyoverdine production: t5.0=48.80, P< 0.0001)
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Our findings indicate that it is difficult to define antivirulence
treatments based on fitness effects [2, 6, 8, 22]. This is because
fitness effects might vary in response to the ecological context of
the media or the infection. For instance, prior work [24] showed
that flucytosine does not affect bacterial growth in trypticase soy
broth dialysate, whereas we found significant fitness effects in
human serum. Endorsing the fitness-based definition would
mean that flucytosine could only be considered as an antiviru-
lence drug in very specific cases, i.e. in one media but not in
another. This might cause confusion when we aim to bring these
new treatment approaches to the clinic. While we agree that it
would be ideal to find compounds that only curb virulence but
not fitness, it seems that such cases are rare and context-
dependent [5, 15]. For all those reasons, we support the more
general definition of antivirulence treatments as advocated
in previous reviews [5, 15]: drugs intended to target bacterial
virulence factors.
Important to note is that even when we use the more general
definition of antivirulence the chances are good that many of the
new treatment approaches are evolutionary more robust than
classical antibiotics. This is nicely illustrated in the case of gal-
lium, where we found that partially resistant mutants only spor-
adically occurred. Given the mutation rate in P. aeruginosa and the
number of generations that occurred in our experiment, the fre-
quency of such mutants should be much higher if they had
experienced a clear selective advantage (Table 2). Our data thus
highlight that it is important to distinguish between the appear-
ance of resistant mutants and their evolutionary potential to
spread through populations.
At the mechanistic level, we isolated mutants with increased
pyocyanin production, a potential mechanism to by-pass gallium-
mediated pyoverdine quenching. Pyocyanin is a redox active mol-
ecule that can extracellularly reduce ferric to ferrous iron [18, 58].
The upregulation of pyocyanin was associated with mutations in
mvaU, encoding a positive regulator of pyocyanin production, and
vfr, encoding a global virulence factor regulator [10]. Mutations in
Vfr can activate PQS (Pseudomonas Quinolon Signal) synthesis,
which is known to promote pyocyanin and pyoverdine synthesis [60,
68]. At the evolutionary level, however, the selective advantage of
these mutations seemed to be compromised because they
occurred only in some of the sequenced clones (Table 1). One
plausible explanation for their sporadic appearance is that
pyocyanin could serve as a public good, reducing iron outside the
cell, thereby generating benefits for other individuals in the vicinity,
including the drug-susceptible wildtype cells. This scenario would
support the argument that antivirulence strategies should target
collective traits, because this would prevent resistant mutants to fix
in populations [12, 14, 16, 19, 20]. The relative success of these
mutants is then determined by the viscosity of the environment,
determining the shareability of secreted compounds [69], and the
potential for negative-frequency dependent selection, where strain
frequency settles at an intermediate ratio [70–72].
The pattern clearly differed for flucytosine, where we found per-
vasive resistance evolution. Although it is not exactly known how
flucytosine inhibits pyoverdine synthesis, we argue that resistance
evolution could mainly be caused by negative effects on other
traits than pyoverdine synthesis. Flucytosine undergoes several
enzymatic modifications within the cell, finally resulting in
fluorinated ribonucleotides. While flucytosine was shown to in-
hibit pyoverdine synthesis [24], it likely also interferes with nucleo-
tide synthesis, which might compromise RNA functionality more
generally [73]. This sets the stage for selection to favor mutants
with alleviated fitness costs under drug exposure. Our results
suggest that cells achieved this through mutations in upp.
The scheme depicted in Fig. 5A shows that the essential pyrimi-
dine nucleotide precursor UMP can be synthesized either through
the salvage pathways reutilizing exogenous free bases and nucleo-
sides, or via a de novo biosynthesis pathway using L-glutamine or
L-aspartate. While the salvage pathway is typically preferred be-
cause it requires less energy, it generates the harmful fluoro-UMP
under flucytosine treatment. Thus, the abolishment of the salvage
pathway through mutations in upp and the switching to the de
novo biosynthesis pathway provides a selective advantage under
flucytosine exposure. The notion that off-target effects might
Table 2. Estimation of mutation supply during experimental evolution
Treatment Population
bottleneck
(CFU)
Number of cell
divisionsa
Expected
mutationsb in
any nucleotide
Expected
mutationsb
in mvaUc
Expected
mutationsb
in vfrc
Expected
mutationsb
in uppc
No drug 2.1105 8.41010 83.9 3.0104 5.4104 5.4104
Gallium low 1.9105 3.51010 34.8 1.2104 2.2104 2.2104
Gallium high 4.8104 8.7109 8.7 3.0103 5.6103 5.6103
Flucytosine low 9.8104 1.81010 17.4 6.2103 1.1104 1.1104
Flucytosine high 4.8104 8.7109 8.7 3.1103 5.6103 5.6103
aAcross all 8 replicated population and 20 transfers.
bAssuming a mutation rate of 109 per nucleotide per cell division for P. aeruginosa PAO1 [79].
cConsidering only the length of the coding sequence (354 bp for mvaU, 645 bp for vfr, 639 bp for upp).
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compromise the evolutionary robustness of antivirulence drugs,
is also supported by the work of Maeda et al. [17]. They showed
that resistance to the quorum-quenching compound C-30
(brominated furanone) evolves repeatedly via upregulation of a
drug efflux pump. The spread of these mutants in their experiment
can be explained by the fact that quorum quenching did not only
inhibit virulence factor production, but also compromised the
ability of cells to grow in adenosine medium, which requires a
functional quorum sensing system [74].
CONCLUSIONS AND IMPLICATIONS
Our work advances research on antivirulence drugs on multiple
fronts. First, it shows that resistant phenotypes are difficult to define,
as they can involve the restoration of growth, the resumption of
virulence factor production, and/or the activation of a bypassing
mechanism. Detailed phenotypic and genotypic analyses, as those
proposed in our study, are required to disentangle background adap-
tation from resistance evolution. Second, we show that antivirulence
approaches are neither completely evolution-proof nor does the no-
tion ‘all roads lead to resistance’ apply [75]. A detailed evolutionary
analysis for each individual drug is required to assess its position on
the continuum between the two extremes. Third, we advocate
the application of more rigorous evolutionary approaches to
quantify resistance evolution. While there are rigorous stand-
ards to describe the precise molecular mode of action of a novel
antibacterial [21, 76], there is much room for improvement for
standards regarding the quantification and characterization of
resistance evolution [77, 78].
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